Home/Filings/4/0001193125-26-003116
4//SEC Filing

ZANTE GREG 4

Accession 0001193125-26-003116

CIK 0001607678other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 8:31 PM ET

Size

17.4 KB

Accession

0001193125-26-003116

Insider Transaction Report

Form 4
Period: 2026-01-02
ZANTE GREG
Chief Financial Officer
Transactions
  • Award

    Common Stock, par value $0.00001 per share

    2026-01-02+41,000215,483 total
  • Award

    Common Stock, par value $0.00001 per share

    2026-01-02+32,049247,532 total
  • Sale

    Common Stock, par value $0.00001 per share

    2026-01-05$32.30/sh31,961$1,032,180215,571 total
  • Sale

    Common Stock, par value $0.00001 per share

    2026-01-05$33.38/sh13,900$464,021201,671 total
  • Sale

    Common Stock, par value $0.00001 per share

    2026-01-05$34.24/sh10,300$352,635191,371 total
  • Sale

    Common Stock, par value $0.00001 per share

    2026-01-05$32.09/sh1,500$48,133189,891 total
  • Award

    Stock Option (Right to Buy)

    2026-01-02+91,00091,000 total
    Exercise: $35.42Exp: 2036-01-02Common Stock (91,000 underlying)
Footnotes (9)
  • [F1]Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
  • [F2]Includes 104 shares acquired on May 20, 2025 and 787 shares acquired on November 20, 2025 pursuant to the Issuer's 2024 Employee Stock Purchase Plan.
  • [F3]The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal.
  • [F4]These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3.
  • [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F6]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F7]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F8]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F9]25% of the shares subject to the option will vest on each anniversary of the grant date.

Documents

1 file

Issuer

Viking Therapeutics, Inc.

CIK 0001607678

Entity typeother

Related Parties

1
  • filerCIK 0001264949

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:31 PM ET
Size
17.4 KB